10-Q: Salarius Pharmaceuticals Faces Delisting Amid Merger Plans and Financial Uncertainty

Salarius Pharmaceuticals reports Q1 2025 results, highlighting ongoing losses, a proposed merger with Decoy Therapeutics, and challenges to maintain its Nasdaq listing.

Summary

• Salarius Pharmaceuticals reported a net loss of $1.71 million for the three months ended March 31, 2025, compared to a net loss of $1.72 million for the same period in 2024.
• Research and development expenses decreased to $75,532 from $243,002 year-over-year, primarily due to cost-saving measures.
• General and administrative expenses increased to $1.64 million from $1.53 million year-over-year, driven by higher professional expenses related to the merger.
• The company's cash and cash equivalents totaled $1.8 million as of March 31, 2025, which is expected to fund operations into the later part of the second quarter of 2025.
• Salarius is pursuing a merger with Decoy Therapeutics, contingent on securing at least $6.0 million in financing and maintaining its Nasdaq listing.
• The company received a delisting notice from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements and has requested a hearing to appeal the determination.
• Salarius has entered into a securities purchase agreement (ELOC) with C/M Capital Master Fund, LP, and issued shares for proceeds during the quarter.
• The company's ability to continue as a going concern is dependent on the successful completion of the merger or securing additional financing.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant risks and uncertainties, including a Nasdaq delisting notice and limited cash reserves. The proposed merger offers a potential path forward, but its success is not guaranteed.

Positives

• The company is actively pursuing a merger with Decoy Therapeutics, which could provide a strategic path forward.
• Cost-saving measures have been implemented, leading to a decrease in research and development expenses.
• The company has secured some financing through the ELOC agreement, providing additional capital.
• Salarius is appealing the Nasdaq delisting determination, seeking to maintain its listing status.

Negatives

• The company reported a net loss of $1.71 million for Q1 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company received a delisting notice from Nasdaq due to non-compliance with listing rules.
• Cash and cash equivalents are limited, with funding expected to last only into the later part of the second quarter of 2025.
• The merger with Decoy Therapeutics is contingent on securing additional financing and maintaining the Nasdaq listing, creating uncertainty.

Risks

• Failure to regain compliance with Nasdaq listing standards could lead to delisting.
• The merger with Decoy Therapeutics may not be completed, potentially requiring Salarius to pay a termination fee or seek alternative strategic options.
• The company may not be able to raise additional funds when necessary or on acceptable terms.
• The merger may not enhance stockholder value and could create a distraction or uncertainty.
• The company's cost-saving initiatives may not be successful in increasing stockholder value.
• The company faces uncertainties about the paths of its programs and its ability to evaluate and identify a path forward for those programs, particularly given the constraints it has as a small company with limited financial, personnel and other operating resources.
• The company's common stock is subject to delisting from Nasdaq, which would seriously harm the liquidity of Salarius common stock and its ability to raise capital or complete a strategic transaction.

Future Outlook

The company's future is heavily dependent on the successful completion of the merger with Decoy Therapeutics and securing additional financing; failure to do so could lead to dissolution and liquidation.

Management Comments

• We believe that there is presently insufficient funding available to allow us to continue our current and planned clinical programs for a period exceeding 12 months from the date of this filing with the SEC.
• We will continue to require substantial additional capital to continue our operations and any clinical development activities that we determine to advance and will need such additional capital within the next several months to continue to fund our operations beyond the later part of the second quarter of 2025.

Industry Context

The biopharmaceutical industry is highly competitive and capital-intensive, with companies like Salarius facing significant challenges in securing funding and achieving regulatory approvals. The strategic review and merger with Decoy Therapeutics reflect a trend of smaller companies seeking consolidation to enhance their pipelines and financial stability.

Comparison to Industry Standards

• Salarius's cash position of $1.8 million is significantly lower than many of its peers in the clinical-stage biopharmaceutical industry.
• Many comparable companies have secured partnerships or licensing agreements to offset development costs, a strategy Salarius may need to consider if the merger fails.
• The company's reliance on investigator-initiated clinical trials reflects a resource-constrained approach, which may limit the scope and pace of clinical development compared to companies with more robust funding.

Stakeholder Impact

• Shareholders face significant risk of dilution or loss of investment.
• Employees face uncertainty regarding job security.
• The company's ability to develop and commercialize treatments for cancer patients is at risk.
• Suppliers and creditors face potential financial losses if the company is forced to liquidate.

Next Steps

• Appeal the Nasdaq delisting determination.
• Secure the minimum $6.0 million in financing required for the merger with Decoy Therapeutics.
• Obtain stockholder approval for the merger and related proposals.
• Complete the merger with Decoy Therapeutics.
• Present plans to regain compliance with the Minimum Bid Price Requirement and the Equity Standard in connection with the planned merger transaction with Decoy Therapeutics Inc.

Key Dates

Keywords

Merger, Decoy Therapeutics, Nasdaq, Delisting, Financial Results, Q1 2025, Salarius Pharmaceuticals, Going Concern, Financing, Clinical Trials